(HealthDay)—Hydrochlorothiazide use is related to an elevated risk of non-melanoma pores and skin cancer (NMSC), with proof of a dose-response relationship, based on a research revealed on-line Dec. three within the Journal of the American Academy of Dermatology.
Sidsel Arnspang, M.D., from Odense University Hospital in Denmark, and colleagues examined the correlation between hydrochlorothiazide use and the risk of basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). Patients with NMSC have been recognized from the Danish Cancer registry throughout 2004 to 2012. They have been matched in a 1:20 ratio by age and intercourse with controls.
The researchers discovered that greater use of hydrochlorothiazide (≥50,000 mg) was related to odds ratios of 1.29 and three.98 for BCC and SCC, respectively. There have been clear dose-response correlations for hydrochlorothiazide use with BCC and SCC; the chances ratios have been 1.54 and seven.38, respectively, for the very best cumulative dose class (≥200,000 mg). There was no correlation to be used of different diuretics and antihypertensives with NMSC.
“Hydrochlorothiazide use is associated with a substantially increased risk of NMSC, especially SCC,” the authors write.
Two authors disclosed monetary ties to the pharmaceutical business.
Popular blood pressure medicine linked with increased risk of skin cancer